Tech Company Financing Transactions
Dracen Pharmaceuticals Funding Round
Dracen Pharmaceuticals, based in New York, secured $36 million from Deerfield Capital.
Transaction Overview
Company Name
Announced On
3/26/2018
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Investors
Deerfield Capital (Jonathan Leff)
Proceeds Purpose
The funding will use this financing to progress its programs into clinical trials for patients suffering from cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
780 3rd Ave. 45th Floor
New York, NY 10017
USA
New York, NY 10017
USA
Phone
Website
Email Address
Overview
Dracen is a privately-funded biotech company developing drugs in the area of immuno-metabolism. Targeting immuno-metabolism promises to have broad acting effects on modulating immune responses in multiple disease settings.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Estok
Chief Medical Officer
Margaret Dugan
Chief Scientific Officer
Robert Wild
VP - Bus. Development
Mohamed Ragab
VP - Finance
Dennis Bilski
VP - Operations
Francois Lafleur
Browse more venture capital transactions:
Prev: 3/26/2018: BestMile venture capital transaction
Next: 3/26/2018: Candex venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs